ATE554770T1 - Therapeutisches mittel gegen entzündliche darmerkrankungen - Google Patents

Therapeutisches mittel gegen entzündliche darmerkrankungen

Info

Publication number
ATE554770T1
ATE554770T1 AT07737060T AT07737060T ATE554770T1 AT E554770 T1 ATE554770 T1 AT E554770T1 AT 07737060 T AT07737060 T AT 07737060T AT 07737060 T AT07737060 T AT 07737060T AT E554770 T1 ATE554770 T1 AT E554770T1
Authority
AT
Austria
Prior art keywords
inflammatory bowel
bowel disease
therapeutic agent
agent against
against inflammatory
Prior art date
Application number
AT07737060T
Other languages
English (en)
Inventor
Yuji Takebayashi
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE554770T1 publication Critical patent/ATE554770T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT07737060T 2006-04-13 2007-04-12 Therapeutisches mittel gegen entzündliche darmerkrankungen ATE554770T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006110869 2006-04-13
PCT/JP2007/000403 WO2007122812A1 (ja) 2006-04-13 2007-04-12 炎症性腸疾患治療薬

Publications (1)

Publication Number Publication Date
ATE554770T1 true ATE554770T1 (de) 2012-05-15

Family

ID=38624731

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07737060T ATE554770T1 (de) 2006-04-13 2007-04-12 Therapeutisches mittel gegen entzündliche darmerkrankungen

Country Status (11)

Country Link
US (1) US7820686B2 (de)
EP (1) EP2005962B1 (de)
JP (1) JP5058156B2 (de)
KR (1) KR101390144B1 (de)
CN (1) CN101420957B (de)
AT (1) ATE554770T1 (de)
AU (1) AU2007242332B2 (de)
CA (1) CA2649256C (de)
ES (1) ES2382673T3 (de)
TW (1) TWI406858B (de)
WO (1) WO2007122812A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI435725B (zh) * 2007-10-11 2014-05-01 Taiho Pharmaceutical Co Ltd The use of a uracil compound for a prophylactic or therapeutic composition for the preparation of cystitis and hepatitis
TWI429439B (zh) * 2007-10-11 2014-03-11 Taiho Pharmaceutical Co Ltd And a therapeutic agent for inflammatory bowel disease using a uracil derivative as an active ingredient
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
CN102920789A (zh) * 2012-11-29 2013-02-13 中央民族大学 治疗溃疡性结肠炎的药物制剂蒙药嘎日迪及其制备方法
HK1203071A1 (en) 2013-06-17 2015-10-16 大鹏药品工业株式会社 Stabilized crystal of tipiracil hydrochloride, and crystallization method for same
EP3836912B1 (de) * 2018-08-15 2024-05-01 Pharmacyl AB Kombinationen von substitutierten benzamiden und 5-asa-wirkstoffen
MX2021003681A (es) * 2018-10-03 2021-08-19 Akebia Therapeutics Inc Composiciones y metodos para el tratamiento de desordenes inflamatorios.
CN110638803A (zh) * 2019-10-24 2020-01-03 上海长海医院 Dencichine在制备治疗炎性肠病药物中的用途
CA3159601A1 (en) * 2019-11-20 2021-05-27 Angion Biomedica Corp. Methods for treating inflammatory bowel disease
CN111686106B (zh) * 2020-04-05 2022-07-15 温州医科大学附属第一医院 提高Dicer表达的化合物在制备药物中的应用
WO2022047730A1 (en) * 2020-09-04 2022-03-10 Shanghai Pharmaceuticals Holding Co., Ltd. Methods to treat inflammatory bowel disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100424934B1 (ko) 1995-03-29 2004-07-27 다이호야쿠힌고교 가부시키가이샤 우라실유도체및이를함유하는항종양효과증강제및항종양제
JP3746522B2 (ja) 1996-04-05 2006-02-15 麒麟麦酒株式会社 イネ科植物の発芽種子由来のタンパク質および不溶性食物センイを含有する物質並びにその用途
AU699728B2 (en) * 1996-09-24 1998-12-10 Taiho Pharmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives
JP4049477B2 (ja) 1999-03-23 2008-02-20 大鵬薬品工業株式会社 副作用軽減剤

Also Published As

Publication number Publication date
TW200813025A (en) 2008-03-16
EP2005962A2 (de) 2008-12-24
CN101420957A (zh) 2009-04-29
ES2382673T3 (es) 2012-06-12
KR101390144B1 (ko) 2014-04-28
EP2005962B1 (de) 2012-04-25
AU2007242332A1 (en) 2007-11-01
AU2007242332B2 (en) 2012-02-02
EP2005962A4 (de) 2009-09-23
TWI406858B (zh) 2013-09-01
KR20080108999A (ko) 2008-12-16
CA2649256C (en) 2013-09-10
EP2005962A9 (de) 2009-07-15
CN101420957B (zh) 2011-04-13
CA2649256A1 (en) 2007-11-01
HK1127964A1 (en) 2009-10-09
WO2007122812A1 (ja) 2007-11-01
JPWO2007122812A1 (ja) 2009-09-03
US7820686B2 (en) 2010-10-26
US20090209565A1 (en) 2009-08-20
JP5058156B2 (ja) 2012-10-24

Similar Documents

Publication Publication Date Title
ATE554770T1 (de) Therapeutisches mittel gegen entzündliche darmerkrankungen
MY186986A (en) Compositions and methods of use of phorbol esters
MA31663B1 (fr) Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe
AU2012243329A8 (en) 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
EP2174667A4 (de) Mittel zur behandlung von augenentzündungen mit interleukin-6-rezeptorhemmer als wirkstoff
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
IN2014CN02128A (de)
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AR088195A1 (es) Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida
HK1198869A1 (en) Combination treatments for hepatitis c
WO2009051119A1 (ja) ピリミジルインドリン化合物
MX2010002735A (es) Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
RU2010136914A (ru) Средство и продукт питания для профилактики/уменьшения проявлений функционального расстройства пищеварения
HK1206264A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2011116139A3 (en) Improved pharmaceutical compositions comprising cck- 8 and methods of delivery
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
WO2007128086A3 (en) Novel viral replication inhibitor
MX365313B (es) Composición farmacéutica oral que comprende a,a,a-trifluorotimidin a y clorhidrato de 5-cloro-6-(2-iminopirrolidina-1-il)metil-2,4(1h ,3h)-pirimidina diona.
MX355885B (es) Composición farmacéutica de administración oral.
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
MY163762A (en) Therapeutic agent for chronic renal failure
WO2006130532A3 (en) Treatment of liver diseases in which iron plays a role in pathogenesis
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke